GlassScriptPhysician profile
Sheila Rojas
NPI 1619586591
$4,874.16
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $850 · 2022: $2,125 · 2023: $1,855 · 2024: $44.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,899.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $960.93 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $388.23 | 2021-2023 | |
| Lilly USA, LLC | $366.92 | 2021-2023 | Mounjaro |
| Pfizer INC. | $342.24 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $326.54 | 2021-2023 | Fasenra, Breztri, Farxiga |
| Biohaven Pharmaceutical Holding Company LTD. | $307.27 | 2022 | |
| Janssen Pharmaceuticals, INC | $247.07 | 2021-2023 | Xarelto |
| Glaxosmithkline, LLC. | $233.89 | 2022-2023 | Shingrix, Arexvy |
| Kowa Pharmaceuticals America, INC. | $233.50 | 2021-2023 | Seglentis, Livalo |
| Amgen INC. | $210.59 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.45 | 2021-2023 | Spiriva Respimat, Tradjenta, Jardiance |
| Shield Therapeutics INC | $160.82 | 2022-2023 | Accrufer |
| Novo Nordisk INC | $145.10 | 2021-2023 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $144.66 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $128.16 | 2022-2023 | Verquvo, Dificid, Pifeltro |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $107.42 | 2022-2023 | Veozah |
| Sanofi-Aventis U.S. LLC | $96.99 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $84.82 | 2021 | |
| Amarin Pharma, INC. | $59.05 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $57.29 | 2022-2023 | Quviviq |
| Impel Pharmaceuticals INC. | $20.00 | 2023 | Trudhesa |
| Neurelis, INC. | $19.92 | 2023 | Valtoco |
| Esperion Therapeutics, INC. | $18.48 | 2021 | |
| Paratek Pharmaceuticals, INC. | $17.39 | 2021 | |
| Nabriva Therapeutics, Plc | $16.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheila Rojas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.